<DOC>
	<DOCNO>NCT01251562</DOCNO>
	<brief_summary>The primary objective clinical study follow : • To determine MTD assess safety tolerability C31510 administer single 4-hour IV infusion ( nine different dosage ) subject solid tumor The secondary objective study follow : • To evaluate plasma PK estimate renal elimination C31510 administer single 4-hour IV infusion ( nine different dosage ) subject solid tumor The exploratory objective study follow : - To evaluate pharmacodynamic correlate C31510 activity plasma peripheral blood cell - To radiographically evaluate effect C31510 tumor . In selected subject , effect vascular permeability assess digital contrast enhance ( DCE ) -magnetic resonance imaging ( MRI ) - To evaluate tumor response ( preliminary antitumor activity ) repeat administration C31510 - Long-term safety tolerability C31510 repeat administration</brief_summary>
	<brief_title>Safety Study Sterile Compound c31510 Injection Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>The subject histologically confirm solid tumor metastatic unresectable standard curative measure exist longer effective . The subject least 18 year old . The subject ECOG ( Eastern Cooperative Oncology Group ) performance status ≤ 2 . The subject life expectancy great 3 month . The subject organ marrow function follow : ANC &gt; 1500mm3 , platelet &gt; 100,000 dl , hemoglobin &gt; 9 g/dL , bilirubin ≤ 1.5mg/dL , serum creatinine ≤1.5mg/dL creatinine clearance &gt; 60 mL/min , alanine aminotransferase ( ALT ) , aspartate transaminase ( AST ) ≤2.5 time upper limit normal liver involvement ≤5 time upper limit normal liver involvement . The subject capable understanding comply protocol sign informed consent document . Sexually active subject must use accepted method contraception course study . Female patient childbearing potential must negative pregnancy test enrollment . If subject receive three prior regimen cytotoxic chemotherapy , two biological regimen , 3000cGy area contain substantial marrow , cohort review committee ( CRC ) must determine subject suitability prior enrollment . The subject receive chemotherapy radiotherapy within 4 week receive nitrosoureas mitomycin C within 6 week prior enter study . The subject receive antiangiogenesis drug within 4 week prior enter study . The subject receive radiation ≥25 % bone marrow within 4 week C31510IV treatment . The subject receive investigational drug within 30 day first dose study drug . 6 72 The subject recover grade ≤1 adverse event ( AEs ) due investigational drug medication , administer 4 week prior study enrollment . The subject uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . The subject pregnant lactating . The subject know positive human immunodeficiency virus ( HIV ) The subject inability unwillingness abide study protocol cooperate fully investigator designee . Must take Vitamin D3 supplement last 30 day The subject HMGCoA Reductase Inhibitors The subject receive digoxin , digitoxin , lanatoside C type digitalis alkaloids The subject receive Colony Stimulating factor . The use Colony Stimulating factor isf prohibit monitoring DLT study . The subject receive Warfarin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>